Genetic polymorphisms of drug‐metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population
- 25 January 2011
- journal article
- research article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 26 (2) , 295-306
Abstract
CYP2E1, CYP2A6 and CYP3A5 enzymes belong to phase I group of drug‐metabolizing enzymes, which are involved in the metabolism of various compounds and xenobiotics. Presence of polymorphisms in the genes coding for these enzymes results in interindividual variations in drug metabolism, therapeutic response and susceptibility towards various diseases. The frequencies of these variants in genes differ considerably between ethnic groups. This study was carried out to estimate the allele and genotype frequencies of common variants inCYP2E1,CYP2A6andCYP3A5in South Indian population. Six hundred and fifty‐two unrelated healthy volunteers of South Indian origin (Andhra Pradesh, Karnataka, Kerala and Tamil Nadu) were included in this study. Polymerase chain reaction–restriction fragment length polymorphism, allele‐specific PCR, real‐time PCR, SNaPshot and gene sequencing methods were used for the identification of gene polymorphisms. The frequencies ofCYP2E1*1B,CYP2E1*5BandCYP2E1*6alleles in South Indian population were 14.3, 1.3 and 22.4%, respectively. The frequencies ofCYP2A6*2,CYP2A6*4AandCYP2A6*5alleles were found to be 1, 8.9 and 0.7%, respectively. The distribution ofCYP3A5*3allele was 63.5%. There were no variant alleles ofCYP3A5*2,CYP3A5*4andCYP3A5*6in South Indian population. The frequencies ofCYP2E1,CYP2A6andCYP3A5in the South Indian population are distinct from Caucasians, Chinese, Japanese, African Americans and other compared populations. This is the first study conducted in the South Indian population with a larger sample size. The findings of our study provide the basic genetic information for further pharmacogenomic investigations in the population.Keywords
This publication has 68 references indexed in Scilit:
- Reconstructing Indian population historyNature, 2009
- Novel human CYP2A6 alleles confound gene deletion analysisFEBS Letters, 2004
- CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean peopleCancer Letters, 2001
- Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolismFEBS Letters, 1999
- Characterization of Multiple Products of Cytochrome P450 2A6-Catalyzed Cotinine MetabolismChemical Research in Toxicology, 1999
- Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patientsInternational Journal of Cancer, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Restriction fragment length polymorphism of the human CYP 2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancerPharmacogenetics, 1994
- Identification of Cytochrome P450 2E1 as the Predominant Enzyme Catalyzing Human Liver Microsomal Defluorination of Sevoflurane, Isoflurane, and MethoxyfluraneAnesthesiology, 1993
- Genetic polymorphism of cytochrome P4502E1 in a Swedish populationFEBS Letters, 1993